Point-of-care hepatitis B diagnostics — the deployment of rapid immunochromatographic HBsAg tests, dried blood spot (DBS) HBV DNA viral load testing, and portable serology platforms enabling HBV diagnosis and treatment eligibility assessment outside of centralized reference laboratory settings — creating the diagnostic access expansion essential for bridging the gap between HBV disease burden and treatment linkage within the Hepatitis B Treatment Market, with point-of-care testing enabling the healthcare delivery model appropriate for the rural, resource-limited, and mobile populations bearing the highest HBV disease burden in sub-Saharan Africa and Asia.

The diagnosis-to-treatment linkage gap — the diagnostic bottleneck — the WHO HBV cascade of care revealing that while 296 million people are chronically HBV-infected globally, only thirty percent have ever been diagnosed — with the diagnosis gap largest in sub-Saharan Africa (less than twenty percent diagnosed) and Southeast Asia (twenty to thirty percent). The primary barriers to HBV diagnosis in high-burden LMICs: absence of routine HBsAg testing in primary care; laboratory infrastructure (phlebotomy, cold chain, equipment) required for centralized immunoassay testing unavailable at community level; delayed or lost results preventing treatment linkage; cost of testing relative to per-capita health expenditure. The point-of-care (POC) HBsAg rapid test addressing all these barriers: fingerstick blood sample, fifteen to twenty minute result at point of care, no laboratory equipment, ambient temperature stability — enabling HBsAg testing in any healthcare setting from district hospital to community health post to mobile testing van.

WHO-prequalified POC HBsAg tests — the market leaders — the WHO Prequalification Programme evaluating diagnostic accuracy of rapid HBsAg tests against reference standards, with prequalified tests (SD BIOLINE HBsAg — Abbott, Determine HBsAg — Abbott, VIKIA HBsAg — bioMérieux) achieving sensitivity ninety-five to ninety-nine percent and specificity ninety-eight to ninety-nine percent — performance equivalent to laboratory immunoassay for screening purposes. The WHO Prequalification stamp enabling UNITAID, Global Fund, and PEPFAR procurement of prequalified POC tests for national HBV testing programs — with bulk procurement pricing ($0.60–$2.00 per test) making POC HBsAg testing affordable for national elimination programs in low-income countries.

DBS HBV DNA viral load testing — the rural treatment monitoring solution — the collection of a few drops of capillary whole blood onto filter paper cards (Whatman 903, Ahlstrom 226 — standard DBS cards used for newborn screening), drying at ambient temperature, and shipping to central virology laboratory for HBV DNA quantification — enabling HBV DNA viral load monitoring without cold chain, without phlebotomy equipment, and with rural-compatible sample collection. DBS HBV DNA performance: validated against plasma viral load with good correlation; sensitivity approximately ninety to ninety-three percent for HBV DNA above lower limit of quantification; enabling treatment eligibility assessment and monitoring in primary care settings where plasma viral load testing infrastructure is absent. Abbott RealTime HBV DNA assay on DBS, Roche cobas HBV DBS protocol, and FIND (Foundation for Innovative New Diagnostics) validated protocols providing the laboratory methodology enabling national DBS viral load programs in sub-Saharan Africa.

Do you think the development of fully integrated point-of-care tests combining HBsAg detection, HBV DNA quantification, and treatment eligibility determination (ALT, hepatic function markers) in a single device will be technically and commercially achievable within the next decade — enabling true one-stop HBV diagnosis and treatment initiation at the community level?

FAQ

What diagnostic tests are included in a comprehensive hepatitis B workup and what do the results indicate? Comprehensive HBV diagnostic panel: screening: HBsAg (hepatitis B surface antigen): positive = chronic or acute HBV infection; screening test of choice; rapid POC or laboratory immunoassay; anti-HBs (hepatitis B surface antibody): positive = immunity (vaccine-induced or resolved infection); protective level ≥10 mIU/mL; anti-HBc total (hepatitis B core antibody): positive = past or present HBV exposure; alone (anti-HBc+/HBsAg−/anti-HBs−): possible occult HBV (HBsAg negative but HBV DNA detectable); confirmation of HBV exposure; acute hepatitis workup: anti-HBc IgM: acute HBV infection marker; elevated in past six months of infection; HBsAg quantitation (qHBsAg): quantitative HBsAg level; IU/mL; predicting treatment response (peg-interferon); monitoring antiviral effect; HBV DNA quantitation: viral load (IU/mL or copies/mL); treatment eligibility; monitoring treatment response; HBeAg/anti-HBe: HBeAg+ = higher viral load, higher infectivity; anti-HBe+ = lower viral replication (usually); HBeAg seroconversion = treatment response marker; HBV genotype: genotyping A-H; implications for peg-interferon response; HCC risk (genotype C); liver assessment: ALT, AST, GGT: hepatic inflammation; bilirubin, albumin, INR: liver function (severity); complete blood count: thrombocytopenia → portal hypertension; creatinine: renal function (TAF vs TDF decision); fasting lipids, glucose: metabolic assessment; liver fibrosis assessment: FibroScan (transient elastography): liver stiffness measurement; METAVIR equivalent staging; non-invasive; FIB-4 index: age × AST / (platelets × √ALT); <1.45 = low fibrosis; >3.25 = significant fibrosis; liver biopsy: rarely needed; when non-invasive discordant; HDV RNA: if anti-HDV positive; delta hepatitis coinfection; AFP + ultrasound: HCC surveillance for high-risk patients.

How are digital health and mobile technology platforms improving HBV patient engagement and treatment adherence? Digital health in HBV management: patient registry and recall systems: electronic patient registries: tracking HBV patients; reminder systems for surveillance ultrasound; viral load monitoring; appointment attendance; CASCADE-B program: pilot in high-burden settings; SMS-based appointment reminders; improving surveillance adherence; mobile health (mHealth) interventions: SMS treatment reminders: daily medication reminder texts; WHO mHealth evidence: SMS improving adherence by eleven to seventeen percent; WHO-recommended for HIV (analogous); implemented for HBV in pilot programs; mHealth apps: HBV patient self-management apps (HepConnect, HBV Ally); medication tracking; appointment scheduling; result notification; community health worker (CHW) digital tools: tablet-based testing and counseling algorithms; CHW-facilitated POC testing and referral; electronic data capture for program monitoring; telemedicine: specialist consultation for rural HBV patients; liver specialist HBV management via telemedicine; particularly valuable for: rural patients with limited specialist access; monitoring stable treated patients without requiring travel; post-COVID expansion of telemedicine in hepatology; EMR integration: EHR-based HBV flag: alert when HBsAg+ patient due for surveillance; automatic viral load ordering; treatment eligibility calculation; clinical decision support alerts; patient portal: lab result delivery; medication refill management; program monitoring: real-time cascade of care tracking; testing-to-treatment linkage monitoring; treatment adherence dashboards; program adjustment based on real-time data; evidence: HBV digital health limited published RCT; extrapolating from HIV/HCV literature; pilot data showing improved engagement; randomized digital health HBV trial needed.

#HBVDiagnostics #HepatitisBTreatmentMarket #PointOfCareTesting #HBVelimination #HepatitisB